Dominique Schols

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Living Beings

Chemicals & Drugs

Anatomy

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Jenabian Mohammad-Ali; Saïdi Héla; Charpentier Charlotte; Van Herrewege Yven; Son Jong Chan; Schols Dominique; Balzarini Jan; Vanham Guido; Bélec Laurent;
In vitro synergistic activity against CCR5-tropic HIV-1 with combinations of potential candidate microbicide molecules HHA, KRV2110 and enfuvirtide (T20).
François Katrien O; Pannecouque Christophe; Auwerx Joeri; Lozano Virginia; Pérez-Pérez Maria-Jésus; Schols Dominique; Balzarini Jan
The phthalocyanine prototype derivative Alcian Blue is the first synthetic agent with selective anti-human immunodeficiency virus activity due to its gp120 glycan-binding potential.
Huskens Dana; Vermeire Kurt; Profy Albert T; Schols Dominique
The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Dominique Schols (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Jenabian Mohammad-Ali; Saïdi Héla; Charpentier Charlotte; Van Herrewege Yven; Son Jong Chan; Schols Dominique; Balzarini Jan; Vanham Guido; Bélec Laurent;
In vitro synergistic activity against CCR5-tropic HIV-1 with combinations of potential candidate microbicide molecules HHA, KRV2110 and enfuvirtide (T20).
The Journal of antimicrobial chemotherapy 2009;64(6):1192-5.
2009: François Katrien O; Pannecouque Christophe; Auwerx Joeri; Lozano Virginia; Pérez-Pérez Maria-Jésus; Schols Dominique; Balzarini Jan
The phthalocyanine prototype derivative Alcian Blue is the first synthetic agent with selective anti-human immunodeficiency virus activity due to its gp120 glycan-binding potential.
Antimicrobial agents and chemotherapy 2009;53(11):4852-9.
2009: Huskens Dana; Vermeire Kurt; Profy Albert T; Schols Dominique
The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1.
Antiviral research 2009;84(1):38-47.
2009: Vermeire Kurt; Van Laethem Kristel; Janssens Wouter; Bell Thomas W; Schols Dominique
Human immunodeficiency virus type 1 escape from cyclotriazadisulfonamide-induced CD4-targeted entry inhibition is associated with increased neutralizing antibody susceptibility.
Journal of virology 2009;83(18):9577-83.
2009: Auwerx Joeri; François Katrien O; Vanstreels Els; Van Laethem Kristel; Daelemans Dirk; Schols Dominique; Balzarini Jan
Capture and transmission of HIV-1 by the C-type lectin L-SIGN (DC-SIGNR) is inhibited by carbohydrate-binding agents and polyanions.
Antiviral research 2009;83(1):61-70.
2009: Alen Marijke M F; Kaptein Suzanne J F; De Burghgraeve Tine; Balzarini Jan; Neyts Johan; Schols Dominique
Antiviral activity of carbohydrate-binding agents and the role of DC-SIGN in dengue virus infection.
Virology 2009;387(1):67-75.
2009: Struyf Sofie; Noppen Samuel; Loos Tamara; Mortier Anneleen; Gouwy Mieke; Verbeke Hannelien; Huskens Dana; Luangsay Souphalone; Parmentier Marc; Geboes Karel; Schols Dominique; Van Damme Jo; Proost Paul
Citrullination of CXCL12 differentially reduces CXCR4 and CXCR7 binding with loss of inflammatory and anti-HIV-1 activity via CXCR4.
Journal of immunology (Baltimore, Md. : 1950) 2009;182(1):666-74.
2008: Brouwers Joachim; Vermeire Kurt; Schols Dominique; Augustijns Patrick
Development and in vitro evaluation of chloroquine gels as microbicides against HIV-1 infection.
Virology 2008;378(2):306-10.
2008: François Katrien O; Auwerx Joeri; Schols Dominique; Balzarini Jan
Simian immunodeficiency virus is susceptible to inhibition by carbohydrate-binding agents in a manner similar to that of HIV: implications for further preclinical drug development.
Molecular pharmacology 2008;74(2):330-7.
2008: Vermeire Kurt; Brouwers Joachim; Van Herrewege Yven; Le Grand Roger; Vanham Guido; Augustijns Patrick; Bell Thomas W; Schols Dominique
CADA, a potential anti-HIV microbicide that specifically targets the cellular CD4 receptor.
Current HIV research 2008;6(3):246-56.
2008: Pollicita M; Schols D; Aquaro S; Peumans W J; Van Damme E J M; Perno C F; Balzarini J
Carbohydrate-binding agents (CBAs) inhibit HIV-1 infection in human primary monocyte-derived macrophages (MDMs) and efficiently prevent MDM-directed viral capture and subsequent transmission to CD4+ T lymphocytes.
Virology 2008;370(2):382-91.
2008: Huskens Dana; Vermeire Kurt; Vandemeulebroucke Elise; Balzarini Jan; Schols Dominique
Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent.
The international journal of biochemistry & cell biology 2008;40(12):2802-14.
2007: Rosenkilde Mette M; Gerlach Lars-Ole; Hatse Sigrid; Skerlj Renato T; Schols Dominique; Bridger Gary J; Schwartz Thue W
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
The Journal of biological chemistry 2007;282(37):27354-65.
2007: Vermeire Kurt; Lisco Andrea; Grivel Jean-Charles; Scarbrough Emily; Dey Kaka; Duffy Noah; Margolis Leonid; Bell Thomas W; Schols Dominique
Design and cellular kinetics of dansyl-labeled CADA derivatives with anti-HIV and CD4 receptor down-modulating activity.
Biochemical pharmacology 2007;74(4):566-78.
2007: Huskens Dana; Princen Katrien; Schreiber Michael; Schols Dominique
The role of N-glycosylation sites on the CXCR4 receptor for CXCL-12 binding and signaling and X4 HIV-1 viral infectivity.
Virology 2007;363(2):280-7.
2007: Hatse Sigrid; Huskens Dana; Princen Katrien; Vermeire Kurt; Bridger Gary J; De Clercq Erik; Rosenkilde Mette M; Schwartz Thue W; Schols Dominique
Modest human immunodeficiency virus coreceptor function of CXCR3 is strongly enhanced by mimicking the CXCR4 ligand binding pocket in the CXCR3 receptor.
Journal of virology 2007;81(7):3632-9.
2007: Stevens Miguel; Pollicita Michela; Pannecouque Christophe; Verbeken Erik; Tabarrini Oriana; Cecchetti Violetta; Aquaro Stefano; Perno Carlo Federico; Fravolini Arnaldo; De Clercq Erik; Schols Dominique; Balzarini Jan
Novel in vivo model for the study of human immunodeficiency virus type 1 transcription inhibitors: evaluation of new 6-desfluoroquinolone derivatives.
Antimicrobial agents and chemotherapy 2007;51(4):1407-13.
2007: Huskens Dana; Van Laethem Kristel; Vermeire Kurt; Balzarini Jan; Schols Dominique
Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12.
Virology 2007;360(2):294-304.
2007: Lisco Andrea; Grivel Jean-Charles; Biancotto Angélique; Vanpouille Christophe; Origgi Francesco; Malnati Mauro S; Schols Dominique; Lusso Paolo; Margolis Leonid B
Viral interactions in human lymphoid tissue: Human herpesvirus 7 suppresses the replication of CCR5-tropic human immunodeficiency virus type 1 via CD4 modulation.
Journal of virology 2007;81(2):708-17.
2007: Balzarini Jan; Van Herrewege Yven; Vermeire Kurt; Vanham Guido; Schols Dominique
Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes.
Molecular pharmacology 2007;71(1):3-11.
2007: Balzarini Jan; Van Laethem Kristel; Daelemans Dirk; Hatse Sigrid; Bugatti Antonella; Rusnati Marco; Igarashi Yasuhiro; Oki Toshikazu; Schols Dominique
Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus.
Journal of virology 2007;81(1):362-73.
2007: Pollicita Michela; Ruff Michael R; Pert Candace B; Polianova Maria T; Schols Dominique; Ranazzi Alessandro; Perno Carlo-Federico; Aquaro Stefano
Profound anti-HIV-1 activity of DAPTA in monocytes/macrophages and inhibition of CCR5-mediated apoptosis in neuronal cells.
Antiviral chemistry & chemotherapy 2007;18(5):285-95.
2006: Aquaro Stefano; Svicher Valentina; Schols Dominique; Pollicita Michela; Antinori Andrea; Balzarini Jan; Perno Carlo Federico
Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies.
Journal of leukocyte biology 2006;80(5):1103-10.
2006: Schols Dominique
HIV coreceptor CXCR4 antagonists.
Current opinion in HIV and AIDS 2006;1(5):361-6.
2006: Balzarini Jan; Van Laethem Kristel; Peumans Willy J; Van Damme Els J M; Bolmstedt Anders; Gago Federico; Schols Dominique
Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes.
Journal of virology 2006;80(17):8411-21.
2006: Perno Carlo Federico; Svicher Valentina; Schols Dominique; Pollicita Michela; Balzarini Jan; Aquaro Stefano
Therapeutic strategies towards HIV-1 infection in macrophages.
Antiviral research 2006;71(2-3):293-300.
2006: Schols Dominique
HIV co-receptor inhibitors as novel class of anti-HIV drugs.
Antiviral research 2006;71(2-3):216-26.
2006: Bell Thomas W; Anugu Sreenivasa; Bailey Patrick; Catalano Vincent J; Dey Kaka; Drew Michael G B; Duffy Noah H; Jin Qi; Samala Meinrado F; Sodoma Andrej; Welch William H; Schols Dominique; Vermeire Kurt
Synthesis and structure-activity relationship studies of CD4 down-modulating cyclotriazadisulfonamide (CADA) analogues.
Journal of medicinal chemistry 2006;49(4):1291-312.
2006: Vermeire Kurt; Schols Dominique; Bell Thomas W
Inhibitors of HIV infection via the cellular CD4 receptor.
Current medicinal chemistry 2006;13(7):731-43.
2005: Balzarini Jan; Van Laethem Kristel; Hatse Sigrid; Froeyen Matheus; Peumans Willy; Van Damme Els; Schols Dominique
Carbohydrate-binding agents cause deletions of highly conserved glycosylation sites in HIV GP120: a new therapeutic concept to hit the achilles heel of HIV.
The Journal of biological chemistry 2005;280(49):41005-14.
2005: Princen Katrien; Schols Dominique
HIV chemokine receptor inhibitors as novel anti-HIV drugs.
Cytokine & growth factor reviews 2005;16(6):659-77.
2005: Turville Stuart G; Vermeire Kurt; Balzarini Jan; Schols Dominique
Sugar-binding proteins potently inhibit dendritic cell human immunodeficiency virus type 1 (HIV-1) infection and dendritic-cell-directed HIV-1 transfer.
Journal of virology 2005;79(21):13519-27.
2005: Vermeire Kurt; Schols Dominique
Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor.
Expert opinion on investigational drugs 2005;14(10):1199-212.
2005: Hatse Sigrid; Princen Katrien; De Clercq Erik; Rosenkilde Mette M; Schwartz Thue W; Hernandez-Abad Pedro E; Skerlj Renato T; Bridger Gary J; Schols Dominique
AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor.
Biochemical pharmacology 2005;70(5):752-61.
2005: Vermeire Kurt; Schols Dominique
Cyclotriazadisulfonamides: promising new CD4-targeted anti-HIV drugs.
The Journal of antimicrobial chemotherapy 2005;56(2):270-2.
2005: Balzarini Jan; Van Laethem Kristel; Hatse Sigrid; Froeyen Matheus; Van Damme Els; Bolmstedt Anders; Peumans Willy; De Clercq Erik; Schols Dominique
Marked depletion of glycosylation sites in HIV-1 gp120 under selection pressure by the mannose-specific plant lectins of Hippeastrum hybrid and Galanthus nivalis.
Molecular pharmacology 2005;67(5):1556-65.
2005: Balzarini Jan; Stevens Miguel; De Clercq Erik; Schols Dominique; Pannecouque Christophe
Pyridine N-oxide derivatives: unusual anti-HIV compounds with multiple mechanisms of antiviral action.
The Journal of antimicrobial chemotherapy 2005;55(2):135-8.
2005: De Klerck Bert; Geboes Lies; Hatse Sigrid; Kelchtermans Hilde; Meyvis Yves; Vermeire Kurt; Bridger Gary; Billiau Alfons; Schols Dominique; Matthys Patrick
Pro-inflammatory properties of stromal cell-derived factor-1 (CXCL12) in collagen-induced arthritis.
Arthritis research & therapy 2005;7(6):R1208-20.
2004: Princen Katrien; Hatse Sigrid; Vermeire Kurt; Aquaro Stefano; De Clercq Erik; Gerlach Lars-Ole; Rosenkilde Mette; Schwartz Thue W; Skerlj Renato; Bridger Gary; Schols Dominique
Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.
Journal of virology 2004;78(23):12996-3006.
2004: Vermeire Kurt; Princen Katrien; Hatse Sigrid; De Clercq Erik; Dey Kaka; Bell Thomas W; Schols Dominique
CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro.
AIDS (London, England) 2004;18(16):2115-25.
2004: Balzarini Jan; Hatse Sigrid; Vermeire Kurt; Princen Katrien; Aquaro Stefano; Perno Carlo-Federico; De Clercq Erik; Egberink Herman; Vanden Mooter Guy; Peumans Willy; Van Damme Els; Schols Dominique
Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection.
Antimicrobial agents and chemotherapy 2004;48(10):3858-70.
2004: Hendrix Craig W; Collier Ann C; Lederman Michael M; Schols Dominique; Pollard Richard B; Brown Stephen; Jackson J Brooks; Coombs Robert W; Glesby Marshall J; Flexner Charles W; Bridger Gary J; Badel Karin; MacFarland Ronald T; Henson Geoffrey W; Calandra Gary;
Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection.
Journal of acquired immune deficiency syndromes (1999) 2004;37(2):1253-62.
2004: Hatse Sigrid; Princen Katrien; Liekens Sandra; Vermeire Kurt; De Clercq Erik; Schols Dominique
Fluorescent CXCL12AF647 as a novel probe for nonradioactive CXCL12/CXCR4 cellular interaction studies.
Cytometry. Part A : the journal of the International Society for Analytical Cytology 2004;61(2):178-88.
2004: Balzarini Jan; Andersson Elin; Schols Dominique; Proost Paul; Van Damme Jo; Svennerholm Bo; Horal Peter; Vahlne Anders
Obligatory involvement of CD26/dipeptidyl peptidase IV in the activation of the antiretroviral tripeptide glycylprolylglycinamide (GPG-NH(2)).
The international journal of biochemistry & cell biology 2004;36(9):1848-59.
2004: Vermeire Kurt; Schols Dominique; Bell Thomas W
CD4 down-modulating compounds with potent anti-HIV activity.
Current pharmaceutical design 2004;10(15):1795-803.
2004: Princen Katrien; Hatse Sigrid; Vermeire Kurt; De Clercq Erik; Schols Dominique
Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists.
Retrovirology 2004;1():2.
2004: Schols Dominique
HIV co-receptors as targets for antiviral therapy.
Current topics in medicinal chemistry 2004;4(9):883-93.
2003: Princen Katrien; Hatse Sigrid; Vermeire Kurt; Bridger Gary J; Skerlj Renato T; De Clercq Erik; Schols Dominique
The antiviral activity of the CXCR4 antagonist AMD3100 is independent of the cytokine-induced CXCR4/HIV coreceptor expression level.
AIDS research and human retroviruses 2003;19(12):1135-9.
2003: Vermeire Kurt; Schols Dominique
Specific CD4 down-modulating compounds with potent anti-HIV activity.
Journal of leukocyte biology 2003;74(5):667-75.
2003: Hatse Sigrid; Princen Katrien; Vermeire Kurt; Gerlach Lars-Ole; Rosenkilde Mette M; Schwartz Thue W; Bridger Gary; De Clercq Erik; Schols Dominique
Mutations at the CXCR4 interaction sites for AMD3100 influence anti-CXCR4 antibody binding and HIV-1 entry.
FEBS letters 2003;546(2-3):300-6.
2003: Princen Katrien; Hatse Sigrid; Vermeire Kurt; De Clercq Erik; Schols Dominique
Evaluation of SDF-1/CXCR4-induced Ca2+ signaling by fluorometric imaging plate reader (FLIPR) and flow cytometry.
Cytometry. Part A : the journal of the International Society for Analytical Cytology 2003;51(1):35-45.
2003: Vermeire Kurt; Bell Thomas W; Choi Heung-Jin; Jin Qi; Samala Meinrado F; Sodoma Andrej; De Clercq Erik; Schols Dominique
The Anti-HIV potency of cyclotriazadisulfonamide analogs is directly correlated with their ability to down-modulate the CD4 receptor.
Molecular pharmacology 2003;63(1):203-10.
2003: Hatse S; Bridger G; de Clercq E; Schols D
X4 HIV-1 induces neuroblastoma cell death by interference with CXCL12/CXCR4 interaction.
Cellular and molecular biology (Noisy-le-Grand, France) 2003;49 Online Pub():OL443-52.
2002: Lane Brian R; Liu Jianguo; Bock Paul J; Schols Dominique; Coffey Michael J; Strieter Robert M; Polverini Peter J; Markovitz David M
Interleukin-8 and growth-regulated oncogene alpha mediate angiogenesis in Kaposi's sarcoma.
Journal of virology 2002;76(22):11570-83.
2002: Vermeire Kurt; Zhang Ying; Princen Katrien; Hatse Sigrid; Samala Meinrado F; Dey Kaka; Choi Heung-Jin; Ahn Youngmi; Sodoma Andrej; Snoeck Robert; Andrei Graciela; De Clercq Erik; Bell Thomas W; Schols Dominique
CADA inhibits human immunodeficiency virus and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor.
Virology 2002;302(2):342-53.
2002: Hatse Sigrid; Princen Katrien; Bridger Gary; De Clercq Erik; Schols Dominique
Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4.
FEBS letters 2002;527(1-3):255-62.
2002: Snoeck Robert; Andrei Graciela; Bodaghi Bahram; Lagneaux Laurence; Daelemans Dirk; de Clercq Erik; Neyts Johan; Schols Dominique; Naesens Lieve; Michelson Susan; Bron Dominique; Otto Michael J; Bousseau Anne; Nemecek Conception; Roy Christine
2-Chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections.
Antiviral research 2002;55(3):413-24.
2002: Lukacs Nicholas W; Berlin Aaron; Schols Dominique; Skerlj Renato T; Bridger Gary J
AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity.
The American journal of pathology 2002;160(4):1353-60.
2002: Proost P; Schols D
[Role of chemokines in the HIV infection process]
Verhandelingen - Koninklijke Academie voor Geneeskunde van België 2002;64(6):403-20.
2001: De Clercq E; Naesens L; De Bolle L; Schols D; Zhang Y; Neyts J
Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8.
Reviews in medical virology 2001;11(6):381-95.
2001: Zhang Y; de Bolle L; Aquaro S; van Lommel A; De Clercq E; Schols D
Productive infection of primary macrophages with human herpesvirus 7.
Journal of virology 2001;75(21):10511-4.
2001: Matthys P; Hatse S; Vermeire K; Wuyts A; Bridger G; Henson G W; De Clercq E; Billiau A; Schols D
AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice.
Journal of immunology (Baltimore, Md. : 1950) 2001;167(8):4686-92.
2001: Struyf S; Menten P; Lenaerts J P; Put W; D'Haese A; De Clercq E; Schols D; Proost P; Van Damme J
Diverging binding capacities of natural LD78beta isoforms of macrophage inflammatory protein-1alpha to the CC chemokine receptors 1, 3 and 5 affect their anti-HIV-1 activity and chemotactic potencies for neutrophils and eosinophils.
European journal of immunology 2001;31(7):2170-8.
2001: Hatse S; Princen K; Gerlach L O; Bridger G; Henson G; De Clercq E; Schwartz T W; Schols D
Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100.
Molecular pharmacology 2001;60(1):164-73.
2001: Aquaro S; Menten P; Struyf S; Proost P; Van Damme J; De Clercq E; Schols D
The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages.
Journal of virology 2001;75(9):4402-6.
2001: De Clercq E; Andrei G; Snoeck R; De Bolle L; Naesens L; Degrève B; Balzarini J; Zhang Y; Schols D; Leyssen P; Ying C; Neyts J
Acyclic/carbocyclic guanosine analogues as anti-herpesvirus agents.
Nucleosides, nucleotides & nucleic acids 2001;20(4-7):271-85.
2001: Malkevitch N; McDermott D H; Yi Y; Grivel J C; Schols D; De Clercq E; Murphy P M; Glushakova S; Collman R G; Margolis L
Coreceptor choice and T cell depletion by R5, X4, and R5X4 HIV-1 variants in CCR5-deficient (CCR5delta32) and normal human lymphoid tissue.
Virology 2001;281(2):239-47.
2001: De Clercq E; Schols D
Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.
Antiviral chemistry & chemotherapy 2001;12 Suppl 1():19-31.
2000: Witvrouw M; Fikkert V; Pluymers W; Matthews B; Mardel K; Schols D; Raff J; Debyser Z; De Clercq E; Holan G; Pannecouque C
Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle.
Molecular pharmacology 2000;58(5):1100-8.
2000: Pluymers W; Neamati N; Pannecouque C; Fikkert V; Marchand C; Burke T R; Pommier Y; Schols D; De Clercq E; Debyser Z; Witvrouw M
Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters.
Molecular pharmacology 2000;58(3):641-8.
2000: Witvrouw M; Weigold H; Pannecouque C; Schols D; De Clercq E; Holan G
Potent anti-HIV (type 1 and type 2) activity of polyoxometalates: structure-activity relationship and mechanism of action.
Journal of medicinal chemistry 2000;43(5):778-83.
2000: Zhang Y; Hatse S; De Clercq E; Schols D
CXC-chemokine receptor 4 is not a coreceptor for human herpesvirus 7 entry into CD4(+) T cells.
Journal of virology 2000;74(4):2011-6.
2000: Daelemans D; Schols D; Witvrouw M; Pannecouque C; Hatse S; van Dooren S; Hamy F; Klimkait T; de Clercq E; VanDamme A M
A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry.
Molecular pharmacology 2000;57(1):116-24.
1999: Bridger G J; Skerlj R T; Padmanabhan S; Martellucci S A; Henson G W; Struyf S; Witvrouw M; Schols D; De Clercq E
Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4.
Journal of medicinal chemistry 1999;42(19):3971-81.
1999: Glushakova S; Yi Y; Grivel J C; Singh A; Schols D; De Clercq E; Collman R G; Margolis L
Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo.
The Journal of clinical investigation 1999;104(5):R7-R11.
1999: Matthys P; Vermeire K; Mitera T; Heremans H; Huang S; Schols D; De Wolf-Peeters C; Billiau A
Enhanced autoimmune arthritis in IFN-gamma receptor-deficient mice is conditioned by mycobacteria in Freund's adjuvant and by increased expansion of Mac-1+ myeloid cells.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(6):3503-10.
1999: Yi Y; Isaacs S N; Williams D A; Frank I; Schols D; De Clercq E; Kolson D L; Collman R G
Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: two distinct mechanisms of HIV-1 dual tropism.
Journal of virology 1999;73(9):7117-25.
1999: Zhang Y; Schols D; De Clercq E
Selective activity of various antiviral compounds against HHV-7 infection.
Antiviral research 1999;43(1):23-35.
1999: Menten P; Struyf S; Schutyser E; Wuyts A; De Clercq E; Schols D; Proost P; Van Damme J
The LD78beta isoform of MIP-1alpha is the most potent CCR5 agonist and HIV-1-inhibiting chemokine.
The Journal of clinical investigation 1999;104(4):R1-5.
1999: Egberink H F; De Clercq E; Van Vliet A L; Balzarini J; Bridger G J; Henson G; Horzinek M C; Schols D
Bicyclams, selective antagonists of the human chemokine receptor CXCR4, potently inhibit feline immunodeficiency virus replication.
Journal of virology 1999;73(8):6346-52.
1999: Esté J A; Cabrera C; Blanco J; Gutierrez A; Bridger G; Henson G; Clotet B; Schols D; De Clercq E
Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4.
Journal of virology 1999;73(7):5577-85.
1999: Pluymers W; Cherepanov P; Schols D; De Clercq E; Debyser Z
Nuclear localization of human immunodeficiency virus type 1 integrase expressed as a fusion protein with green fluorescent protein.
Virology 1999;258(2):327-32.
1999: Struyf S; Proost P; Schols D; De Clercq E; Opdenakker G; Lenaerts J P; Detheux M; Parmentier M; De Meester I; Scharpé S; Van Damme J
CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(8):4903-9.
1999: Proost P; Struyf S; Schols D; Opdenakker G; Sozzani S; Allavena P; Mantovani A; Augustyns K; Bal G; Haemers A; Lambeir A M; Scharpé S; Van Damme J; De Meester I
Truncation of macrophage-derived chemokine by CD26/ dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction.
The Journal of biological chemistry 1999;274(7):3988-93.
1999: Esté J A; Cabrera C; De Clercq E; Struyf S; Van Damme J; Bridger G; Skerlj R T; Abrams M J; Henson G; Gutierrez A; Clotet B; Schols D
Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor.
Molecular pharmacology 1999;55(1):67-73.
1999: Van Damme J; Struyf S; Wuyts A; Van Coillie E; Menten P; Schols D; Sozzani S; De Meester I; Proost P
The role of CD26/DPP IV in chemokine processing.
Chemical immunology 1999;72():42-56.
1998: Schols D; Proost P; Struyf S; Wuyts A; De Meester I; Scharpé S; Van Damme J; De Clercq E
CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity.
Antiviral research 1998;39(3):175-87.
1998: Proost P; Struyf S; Wuyts A; Menten P; De Meester I; Lambeir A M; Scharpé S; Schols D; De Clercq E; Van Damme J
Isolation and identification of naturally modified C-C chemokines MCP-1, MCP-2 and RANTES: effects of posttranslational modifications on receptor usage, chemotactic and anti-HIV-1 activity.
European cytokine network 1998;9(3 Suppl):73-5.
1998: Schols D; De Clercq E
The simian immunodeficiency virus mnd(GB-1) strain uses CXCR4, not CCR5, as coreceptor for entry in human cells.
The Journal of general virology 1998;79 ( Pt 9)():2203-5.
1998: Struyf S; Proost P; Sozzani S; Mantovani A; Wuyts A; De Clercq E; Schols D; Van Damme J
Enhanced anti-HIV-1 activity and altered chemotactic potency of NH2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptor.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(6):2672-5.
1998: Proost P; Struyf S; Schols D; Durinx C; Wuyts A; Lenaerts J P; De Clercq E; De Meester I; Van Damme J
Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha.
FEBS letters 1998;432(1-2):73-6.
1998: Schols D; Esté J A; Cabrera C; De Clercq E
T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use.
Journal of virology 1998;72(5):4032-7.
1998: Proost P; De Meester I; Schols D; Struyf S; Lambeir A M; Wuyts A; Opdenakker G; De Clercq E; Scharpé S; Van Damme J
Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection.
The Journal of biological chemistry 1998;273(13):7222-7.
1998: Esté J A; Cabrera C; Schols D; Cherepanov P; Gutierrez A; Witvrouw M; Pannecouque C; Debyser Z; Rando R F; Clotet B; Desmyter J; De Clercq E
Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir).
Molecular pharmacology 1998;53(2):340-5.
1998: Donzella G A; Schols D; Lin S W; Esté J A; Nagashima K A; Maddon P J; Allaway G P; Sakmar T P; Henson G; De Clercq E; Moore J P
AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.
Nature medicine 1998;4(1):72-7.
1997: Schols D; Struyf S; Van Damme J; Esté J A; Henson G; De Clercq E
Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4.
The Journal of experimental medicine 1997;186(8):1383-8.
1997: Schols D; Proost P; Van Damme J; De Clercq E
RANTES and MCP-3 inhibit the replication of T-cell-tropic human immunodeficiency virus type 1 strains (SF-2, MN, and HE).
Journal of virology 1997;71(10):7300-4.
1997: Schols D; Esté J A; Henson G; De Clercq E
Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4.
Antiviral research 1997;35(3):147-56.
1997: Este J A; Schols D; De Vreese K; Van Laethem K; Vandamme A M; Desmyter J; De Clercq E
Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein.
Molecular pharmacology 1997;52(1):98-104.
1997: Witvrouw M; Balzarini J; Pannecouque C; Jhaumeer-Laulloo S; Esté J A; Schols D; Cherepanov P; Schmit J C; Debyser Z; Vandamme A M; Desmyter J; Ramadas S R; de Clercq E
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus.
Antimicrobial agents and chemotherapy 1997;41(2):262-8.
1996: Schols D; De Clercq E
Human immunodeficiency virus type 1 gp120 induces anergy in human peripheral blood lymphocytes by inducing interleukin-10 production.
Journal of virology 1996;70(8):4953-60.
1996: Balzarini J; Pelemans H; Aquaro S; Perno C F; Witvrouw M; Schols D; De Clercq E; Karlsson A
Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication.
Molecular pharmacology 1996;50(2):394-401.
1996: Leydet A; El Hachemi H; Boyer B; Lamaty G; Roque J P; Schols D; Snoeck R; Andrei G; Ikeda S; Neyts J; Reymen D; Este J; Witvrouw M; De Clercq E
Polyanion inhibitors of human immunodeficiency virus and other viruses. Part 2. Polymerized anionic surfactants derived from amino acids and dipeptides.
Journal of medicinal chemistry 1996;39(8):1626-34.
1995: Neyts J; Reymen D; Letourneur D; Jozefonvicz J; Schols D; Este J; Andrei G; McKenna P; Witvrouw M; Ikeda S
Differential antiviral activity of derivatized dextrans.
Biochemical pharmacology 1995;50(6):743-51.
1994: Pauwels R; Andries K; Debyser Z; Kukla M J; Schols D; Breslin H J; Woestenborghs R; Desmyter J; Janssen M A; De Clercq E
New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogs.
Antimicrobial agents and chemotherapy 1994;38(12):2863-70.
1993: Snoeck R; Andrei G; Neyts J; Schols D; Cools M; Balzarini J; De Clercq E
Inhibitory activity of S-adenosylhomocysteine hydrolase inhibitors against human cytomegalovirus replication.
Antiviral research 1993;21(3):197-216.
1993: Pauwels R; Andries K; Debyser Z; Van Daele P; Schols D; Stoffels P; De Vreese K; Woestenborghs R; Vandamme A M; Janssen C G
Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(5):1711-5.
1993: Balzarini J; Holy A; Jindrich J; Naesens L; Snoeck R; Schols D; De Clercq E
Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine.
Antimicrobial agents and chemotherapy 1993;37(2):332-8.
1992: Snoeck R; Andrei G; Schols D; Balzarini J; De Clercq E
Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1992;11(12):1144-55.
1992: Witvrouw M; Pauwels R; Vandamme A M; Schols D; Reymen D; Yamamoto N; Desmyter J; De Clercq E
Cell type-specific anti-human immunodeficiency virus type 1 activity of the transactivation inhibitor Ro5-3335.
Antimicrobial agents and chemotherapy 1992;36(12):2628-33.
1992: Yamamoto N; Schols D; De Clercq E; Debyser Z; Pauwels R; Balzarini J; Nakashima H; Baba M; Hosoya M; Snoeck R
Mechanism of anti-human immunodeficiency virus action of polyoxometalates, a class of broad-spectrum antiviral agents.
Molecular pharmacology 1992;42(6):1109-17.
1992: Snoeck R; Schols D; Sadzot-Delvaux C; Cloes J M; Andrei G; De Clercq E; Piette J; Rentier B
Flow cytometric method for the detection of gpI antigens of varicella zoster virus and evaluation of anti-VZV agents.
Journal of virological methods 1992;38(2):243-54.
1992: Schols D; Pauwels R; Desmyter J; De Clercq E
Presence of class II histocompatibility DR proteins on the envelope of human immunodeficiency virus demonstrated by FACS analysis.
Virology 1992;189(1):374-6.
1992: Neyts J; Snoeck R; Schols D; Balzarini J; Esko J D; Van Schepdael A; De Clercq E
Sulfated polymers inhibit the interaction of human cytomegalovirus with cell surface heparan sulfate.
Virology 1992;189(1):48-58.
1992: De Clercq E; Yamamoto N; Pauwels R; Baba M; Schols D; Nakashima H; Balzarini J; Debyser Z; Murrer B A; Schwartz D
Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(12):5286-90.
1992: Balzarini J; Neyts J; Schols D; Hosoya M; Van Damme E; Peumans W; De Clercq E
The mannose-specific plant lectins from Cymbidium hybrid and Epipactis helleborine and the (N-acetylglucosamine)n-specific plant lectin from Urtica dioica are potent and selective inhibitors of human immunodeficiency virus and cytomegalovirus replication in vitro.
Antiviral research 1992;18(2):191-207.
1992: Pauwels R; Andries K; Debyser Z; Kukla M; Schols D; Desmyter J; De Clercq E; Janssen P A
TIBO derivatives: a new class of highly potent and specific inhibitors of HIV-1 replication.
Biochemical Society transactions 1992;20(2):509-12.
1992: Balzarini J; Pérez-Pérez M J; San-Félix A; Schols D; Perno C F; Vandamme A M; Camarasa M J; De Clercq E
2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(10):4392-6.
1991: Andrei G; Snoeck R; Schols D; Goubau P; Desmyter J; De Clercq E
Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1991;10(12):1026-33.
1991: Neyts J; Snoeck R; Schols D; Himpens B; De Clercq E
Sensitive, reproducible and convenient fluorometric assay for the in vitro evaluation of anti-cytomegalovirus agents.
Journal of virological methods 1991;35(1):27-38.
1991: Balzarini J; Perno C F; Schols D; De Clercq E
Activity of acyclic nucleoside phosphonate analogues against human immunodeficiency virus in monocyte/macrophages and peripheral blood lymphocytes.
Biochemical and biophysical research communications 1991;178(1):329-35.
1991: Snoeck R; Schols D; Andrei G; Neyts J; De Clercq E
Antiviral activity of anti-cytomegalovirus agents (HPMPC, HPMPA) assessed by a flow cytometric method and DNA hybridization technique.
Antiviral research 1991;16(1):1-9.
1991: Balzarini J; Lee C K; Schols D; De Clercq E
1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) and 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide (EICAR) markedly potentiate the inhibitory effect of 2',3'-dideoxyinosine on human immunodeficiency virus in peripheral blood lymphocytes.
Biochemical and biophysical research communications 1991;178(2):563-9.
1991: Balzarini J; Schols D; Neyts J; Van Damme E; Peumans W; De Clercq E
Alpha-(1-3)- and alpha-(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro.
Antimicrobial agents and chemotherapy 1991;35(3):410-6.
1991: Pauwels R; Schols D
Development of new potent and selective agents against HIV (human immunodeficiency virus).
Verhandelingen - Koninklijke Academie voor Geneeskunde van België 1991;53(6):629-55.
1991: Schols D; Wutzler P; Klöcking R; Helbig B; De Clercq E
Selective inhibitory activity of polyhydroxycarboxylates derived from phenolic compounds against human immunodeficiency virus replication.
Journal of acquired immune deficiency syndromes 1991;4(7):677-85.
1990: Neyts J; Snoeck R; Schols D; Balzarini J; De Clercq E
Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG).
Virology 1990;179(1):41-50.
1990: Nakashima H; Balzarini J; Pauwels R; Schols D; Desmyter J; De Clercq E
Anti-HIV-1 activity of antiviral compounds, as quantitated by a focal immunoassay in CD4+ HeLa cells and a plaque assay in MT-4 cells.
Journal of virological methods 1990;29(2):197-208.
1990: Schols D; Pauwels R; Desmyter J; De Clercq E
Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the viral gp120 glycoprotein expressed by T-cells persistently infected with HIV-1.
Virology 1990;175(2):556-61.
1990: Baba M; De Clercq E; Schols D; Pauwels R; Snoeck R; Van Boeckel C; Van Dedem G; Kraaijeveld N; Hobbelen P; Ottenheijm H
Novel sulfated polysaccharides: dissociation of anti-human immunodeficiency virus activity from antithrombin activity.
The Journal of infectious diseases 1990;161(2):208-13.
1990: Pauwels R; Andries K; Desmyter J; Schols D; Kukla M J; Breslin H J; Raeymaeckers A; Van Gelder J; Woestenborghs R; Heykants J
Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives.
Nature 1990;343(6257):470-4.
1990: Baba M; Schols D; De Clercq E; Pauwels R; Nagy M; Györgyi-Edelényi J; Löw M; Görög S
Novel sulfated polymers as highly potent and selective inhibitors of human immunodeficiency virus replication and giant cell formation.
Antimicrobial agents and chemotherapy 1990;34(1):134-8.
1990: Schols D; Pauwels R; Desmyter J; De Clercq E
Flow cytometric method to monitor the destruction of CD4+ cells following their fusion with HIV-infected cells.
Cytometry 1990;11(6):736-43.
1990: Baba M; Schols D; Pauwels R; Nakashima H; De Clercq E
Sulfated polysaccharides as potent inhibitors of HIV-induced syncytium formation: a new strategy towards AIDS chemotherapy.
Journal of acquired immune deficiency syndromes 1990;3(5):493-9.
1989: Baba M; Tanaka H; De Clercq E; Pauwels R; Balzarini J; Schols D; Nakashima H; Perno C F; Walker R T; Miyasaka T
Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative.
Biochemical and biophysical research communications 1989;165(3):1375-81.
1989: Schols D; Snoeck R; Neyts J; de Clercq E
Detection of immediate early, early and late antigens of human cytomegalovirus by flow cytometry.
Journal of virological methods 1989;26(3):247-54.
1989: Nakashima H; Pauwels R; Baba M; Schols D; Desmyter J; De Clercq E
Tetrazolium-based plaque assay for HIV-1 and HIV-2, and its use in the evaluation of antiviral compounds.
Journal of virological methods 1989;26(3):319-29.
1989: Schols D; Pauwels R; Baba M; Desmyter J; De Clercq E
Syncytium formation and destruction of bystander CD4+ cells cocultured with T cells persistently infected with human immunodeficiency virus as demonstrated by flow cytometry.
The Journal of general virology 1989;70 ( Pt 9)():2397-408.
1989: Balzarini J; Van Aerschot A; Pauwels R; Baba M; Schols D; Herdewijn P; De Clercq E
5-Halogeno-3'-fluoro-2',3'-dideoxyuridines as inhibitors of human immunodeficiency virus (HIV): potent and selective anti-HIV activity of 3'-fluoro-2',3'-dideoxy-5-chlorouridine.
Molecular pharmacology 1989;35(5):571-7.
1989: Schols D; Baba M; Pauwels R; Desmyter J; De Clercq E
Specific interaction of aurintricarboxylic acid with the human immunodeficiency virus/CD4 cell receptor.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(9):3322-6.
1989: Baba M; Schols D; Nakashima H; Pauwels R; Parmentier G; Meijer D K; De Clercq E
Selective activity of several cholic acid derivatives against human immunodeficiency virus replication in vitro.
Journal of acquired immune deficiency syndromes 1989;2(3):264-71.
1989: Schols D; Baba M; Pauwels R; De Clercq E
Flow cytometric method to demonstrate whether anti-HIV-1 agents inhibit virion binding to T4+ cells.
Journal of acquired immune deficiency syndromes 1989;2(1):10-5.
1988: Schols D; Pauwels R; Vanlangendonck F; Balzarini J; De Clercq E
A highly reliable, sensitive, flow cytometric/fluorometric assay for the evaluation of the anti-HIV activity of antiviral compounds in MT-4 cells.
Journal of immunological methods 1988;114(1-2):27-32.
1988: Baba M; Schols D; Pauwels R; Balzarini J; De Clercq E
Fuchsin acid selectively inhibits human immunodeficiency virus (HIV) replication in vitro.
Biochemical and biophysical research communications 1988;155(3):1404-11.
1988: Baba M; Nakajima M; Schols D; Pauwels R; Balzarini J; De Clercq E
Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro.
Antiviral research 1988;9(6):335-43.
1988: Pauwels R; Balzarini J; Baba M; Snoeck R; Schols D; Herdewijn P; Desmyter J; De Clercq E
Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds.
Journal of virological methods 1988;20(4):309-21.
1988: Pauwels R; Balzarini J; Schols D; Baba M; Desmyter J; Rosenberg I; Holy A; De Clercq E
Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents.
Antimicrobial agents and chemotherapy 1988;32(7):1025-30.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Dominique Schols

Research Profile (preview)

Living Beings

Chemicals & Drugs

Anatomy

Physiology

Procedures

Disorders

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Dominique Schols (preview)

All Publications